Literature DB >> 6692422

Regional cancer chemotherapy.

W D Ensminger, J W Gyves.   

Abstract

Regional cancer chemotherapy is a means of exploiting dose-response effects by delivering more drug to regionally confined tumors. Regional chemotherapy can be divided into two major categories, third-space (cerebrospinal, peritoneal, pleural, and pericardial fluid) and intra-arterial treatments. Interest in regional chemotherapy has risen recently for a variety of reasons, including evidence for significantly higher response rates compared to systemic therapies. The applicable pharmacokinetic principles for drug selection have been defined and indicate that regional drug exposure advantage is directly proportional to total-body drug clearance and is inversely proportional to rate of egress from a third-space or to regional blood flow. Reliable drug delivery to the entire region in question is important. The recently introduced totally implanted devices (pumps and ports) make regional therapy more reliable, safe, and convenient. In addition, nuclear medicine scanning techniques have proven useful in assessing drug distribution with regional delivery. Regional therapy may control regional tumor, but extraregional failure may ensue. However, when regional therapy is regionally selective in its toxic effects, systemic therapy may be combined in full doses. Future efforts will need to focus on the development of more potent regional therapies, alone and in combination with systemic therapies, as well as on the validation of such treatments through controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692422

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  15 in total

1.  Malignant lymphoma of the stomach after chemotherapy for hepatocellular carcinoma.

Authors:  I Matsuo; K Omagari; N Ikuno; H Kinoshita; Y Onizuka; M Itsuno; T Nakayama; S Kohno
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

Review 2.  Hepatic arterial chemotherapy for primary and metastatic liver cancers.

Authors:  W Ensminger
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  [Regional chemotherapy of liver metastases].

Authors:  A Encke; C Hottenrott; M Lorenz
Journal:  Langenbecks Arch Chir       Date:  1987

4.  Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system.

Authors:  Mengjie Li; Pritam Thapa; Pallavi Rajaputra; Moses Bio; Cody J Peer; William D Figg; Youngjae You; Sukyung Woo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-09-14       Impact factor: 2.745

5.  Intratumoural administration of cisplatin in slow-release devices. I. Tumour response and toxicity.

Authors:  M J Deurloo; S Bohlken; W Kop; C F Lerk; W Hennink; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats.

Authors:  A Marinelli; D H Pons; J A Vreeken; S K Nagesser; P J Kuppen; U R Tjaden; C J van de Velde
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  [Locoregional chemotherapy of liver metastases of colorectal cancer].

Authors:  A Encke; C Hottenrott; M Lorenz
Journal:  Langenbecks Arch Chir       Date:  1987

Review 8.  Clinical pharmacokinetic advantages of new drug delivery methods for the treatment of liver tumours.

Authors:  J H Anderson; H W Warren; C S McArdle
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 9.  Some aspects of size-dependent differential drug response in primary and metastatic tumors.

Authors:  I Abe; M Suzuki; K Hori; S Saito; H Sato
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

10.  [Effective treatment of peritoneal carcinosis by intraperitoneal cis-diamminedichloroplatinum (c-DDP) administration with systemic sodium thiosulfate protection. Clinical results and pharmacokinetics].

Authors:  H Rückle; G Ehninger; F Jakob; K Wilms
Journal:  Klin Wochenschr       Date:  1986-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.